Huma Therapeutics, a global digital health company, has joined forces with Merck KGaA, Darmstadt, Germany, to develop a digital solution aimed at enhancing the understanding and management of cancer patients and their treatment.
The collaborative initiative, known as the Cross-Indication Disease Management Platform, will be accessible to patients undergoing cancer treatments provided by Merck KGaA, Darmstadt, Germany.
The initial release of this direct-to-patient solution is planned for 2024, and it will offer support to patients with urothelial carcinoma in the UK.
Making use of Huma’s disease-agnostic Software as a Medical Device (SaMD) technology platform, which is the first of its kind to attain both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, the partnership between Huma and Merck KGaA, Darmstadt, Germany aims to enhance patients’ comprehension of their medical condition and treatment protocols, promoting adherence to prescribed treatments.
The collaboration also aims to facilitate open and productive discussions between patients and their healthcare teams, provide timely and relevant educational content and foster connections between patients and caregivers, creating a supportive community network.
Huma CEO and founder Dan Vahdat said: “Our collaboration with Merck KGaA, Darmstadt, Germany is a pivotal step towards amplifying our impact on patient care both at the individual and systemic level.
“Our recent regulatory achievements mark a significant milestone, streamlining our ability to introduce innovative digital companion applications, alongside more sophisticated AI algorithms that may support patients and healthcare professionals alike.
“We are thrilled to join forces with Merck KGaA, Darmstadt, Germany, to develop this ambitious oncology platform.”
Huma chief medical officer Mert Aral said: “A number of well-designed scientific studies have underscored the pivotal role digital health technologies can play in optimising care pathways in oncology, improving patient outcomes.
“In this significant collaboration with Merck KGaA, Darmstadt, Germany, the project strives to simplify the complex journey that cancer patients often face.
“The goal is straightforward – to deepen the understanding of patients about their condition, help them to navigate intricate care pathways seamlessly and to facilitate sustained adherence to therapies.”
